摘要
目的探讨左卡尼丁注射液联合促红细胞生成素治疗肾性贫血(RA)的临床效果及安全性。方法选取2020年2月至2022年6月我院收治的102例RA患者,随机分为两组各51例。对照组采用促红细胞生成素治疗,观察组在对照组基础上采用左卡尼丁注射液治疗。两组均连续治疗3个月。比较两组的临床疗效,Hb、HCT、TAST、SF水平及不良反应情况。结果观察组治疗总有效率为92.16%,高于对照组的76.47%(P<0.05)。治疗3个月后,观察组的Hb、HCT、TAST、SF水平均高于对照组(P<0.05)。治疗期间,两组的不良反应发生率(7.84%vs.11.76%)比较,差异无统计学意义(P>0.05)。结论左卡尼丁注射液联合促红细胞生成素治疗RA的效果显著,可明显改善患者的贫血、营养状况,且安全可靠。
Objective To explore the clinical effect and safety of levocarnitine injection combined with erythropoietin in the treatment of renal anemia(RA).Methods 102 RA patients admitted to our hospital from February 2020 to June 2022 were randomly divided into two groups,with 51 cases in each group.The control group was treated with erythropoietin,and the observation group was treated with levocarnitine injection on the basis of the control group.Both groups were treated continuously for 3 months.The clinical efficacy,Hb,HCT,TAST,SF levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 92.16%,higher than 76.47%in the control group(P<0.05).After 3 months of treatment,the Hb,HCT,TAST and SF levels of the observation group were higher than those of the control group(P<0.05).During treatment,no statistical difference was found in the incidence of adverse reactions(7.84%vs.11.76%)between the two groups(P>0.05).Conclusions Levocarnitine injection combined with erythropoietin has significant effect in the treatment of RA,which can significantly improve the anemia and nutritional status,and is safe and reliable.
作者
苗小勇
王蛟
MIAO Xiaoyong;WANG Jiao(Department of Nephrology,Wenxian People's Hospital,Jiaozuo 45480,China)
出处
《临床医学工程》
2023年第11期1527-1528,共2页
Clinical Medicine & Engineering
